Cannabivarol (CAS 33745-21-0) is a cannabinoid derivative with potential analgesic and neuroprotective properties. Its structural complexity and lipophilicity present challenges in drug development but also offer opportunities for targeted therapeutic applications.
Name :
CannabivarolCAS No. :
33745-21-0MF :
C₁₉H₂₂O₂MW :
282.38Purity :
98%Appearance :
White to off-white crystalline solid (predicted)Storage Condition :
Sparingly soluble in ethanol, methanol, and DMSOChemical Properties
Chemical Name: 6,6,9-Trimethyl-3-propylbenzo[c]chromen-1-ol
CAS Number: 33745-21-0
Molecular Formula: C₁₉H₂₂O₂
Molecular Weight: 282.38 g/mol
Appearance: White to off-white crystalline solid (predicted) .
Melting Point: Not explicitly reported, but likely decomposes above 300°C (predicted) .
Boiling Point: 454.1°C (predicted) .
Density: 1.087 g/cm³ (predicted) .
Solubility:
Poorly soluble in water.
Moderately soluble in organic solvents (ethanol, methanol, DMSO).
Synonyms:
Cannabivarol
Cannabivarin
CBV
Chemical Structure
Core Structure: A benzopyran derivative with a trimethyl-substituted benzene ring fused to a pyran ring.
Functional Groups:
Hydroxyl (-OH) group at the 1-position of the pyran ring.
Propyl chain at the 3-position.
Stereochemistry: No explicit chiral centers reported in the search results.
Key Applications
Pharmacological Activity:
Cannabinoid Receptor Modulation: Binds to CB₁ and CB₂ receptors, exhibiting potential analgesic and anti-inflammatory effects .
Antioxidant Properties: Investigated for mitigating oxidative stress in preclinical studies.
Research Use:
Studied as a candidate for treating chronic pain, epilepsy, and neurodegenerative disorders.
Explored in combination therapies with other cannabinoids (e.g., THC, CBD).
Safety and Handling
Toxicity:
Acute toxicity data unavailable; likely low toxicity given structural similarity to CBD.
Avoid prolonged exposure to high concentrations.
Regulatory Status:
Not classified as a controlled substance in most jurisdictions but may require regulatory review for human use.
Synthesis and Production
Synthesis Routes:
Hydroxylation of CBDV: Enzymatic or chemical modification of cannabidivarin to introduce the hydroxyl group.
Biocatalytic Methods: Use of microbial enzymes for selective hydroxylation.
Purification: Recrystallization from ethanol or column chromatography.
FAQ
Q1: What is Cannabivarin and how is it different from CBD or THC?
A: Cannabivarin (CBV) is a propyl analogue of Cannabidiol (CBD). Its key difference is a shorter three-carbon side chain (propyl) instead of the five-carbon pentyl chain found in CBD and THC. This structural variation significantly alters its interaction with biological targets.
Q2: Is Cannabivarin psychoactive?
A: No. Current research classifies Cannabivarin as non-psychoactive because it does not have a significant binding affinity for the CB1 receptor in the central nervous system, which is responsible for the psychoactive effects of THC.
Q3: What is the main research interest in this compound?
A: Primary research focuses on its potential therapeutic properties, which may include anticonvulsant, anti-inflammatory, and appetite-modulating effects. It is also a crucial compound for studying the structure-activity relationships (SAR) of cannabinoids.
Q4: What is the typical purity available and how should it be stored?
A: It is typically available as a solid or oil at high purity grades (e.g., >95% or >98% by HPLC). For maximum stability, it must be stored sealed under an inert atmosphere (N₂ or Argon), protected from light, and at low temperatures (-20°C) to prevent oxidation and degradation.
Q5: Is there a distinction between acidic (CBV-A) and neutral (CBV) forms?
A: Yes. The compound with CAS 33745-21-0 typically refers to the neutral, decarboxylated form (CBV). The acidic precursor is Cannabivarinic acid (CBV-A). It is critical to confirm which form is supplied for your research, as their biological activities and stability differ.
Q6: Is Cannabivarin a controlled substance?
A: The legal status of minor cannabinoids is complex and varies by country and state. While often not explicitly listed, it may be considered an analog under broad laws like the US Federal Analog Act. It is the purchaser's responsibility to verify the regulatory status in their region prior to acquisition.
Cannabichromene (CBC) (CAS 20675-51-8) is a non-psychoactive cannabinoid recognized for its potential synergistic role in the "entourage effect" and its distinct pharmacological profile. Unlike THC, it does not bind strongly to CB1 receptors but interacts with other targets such as TRPV and serotonin receptors, contributing to its studied anti-inflammatory, antimicrobial, and neurogenesis-promoting properties. Though typically found in low concentrations in cannabis cultivars, its emerging therapeutic potential makes it a compound of growing interest in neurological and inflammatory disorder research.
Details
Cannabigerol (CBG) (CAS 25654-31-3) is a non-psychoactive cannabinoid often referred to as the "mother cannabinoid" or "stem cell cannabinoid" because it serves as the direct biosynthetic precursor to other major cannabinoids like THC, CBD, and CBC in the cannabis plant. Though typically present in low concentrations in most cultivars, it exhibits a broad pharmacological profile, interacting with CB1, CB2, and other receptors, and is researched for its potential anti-inflammatory, antimicrobial, and neuroprotective properties. Its critical role in cannabinoid biosynthesis and its emerging therapeutic promise make it a high-value compound for both agricultural and pharmaceutical development.
Details
Cannabinol (CAS 521-35-7) is a mildly psychoactive cannabinoid formed primarily through the oxidative degradation of tetrahydrocannabinol (THC), often accumulating in aged cannabis material. It exhibits a unique pharmacological profile characterized by a higher affinity for CB2 receptors than CB1, contributing to its potential therapeutic applications in sleep regulation, pain relief, and as an anti-inflammatory agent. While its psychoactive effects are significantly weaker than THC, its role as a marker for cannabis aging and its emerging bioactivity make it a compound of growing interest in medicinal and analytical research.
Details
Cannabidivarol (CAS 24274-48-4) is a non-psychoactive propyl analogue of cannabidiol (CBD), distinguished by its shorter three-carbon side chain instead of CBD’s pentyl chain. This structural variation influences its pharmacological profile, enhancing its research relevance as a potential therapeutic agent, particularly for its noted anticonvulsant properties and emerging applications in treating neurological disorders such as epilepsy. As a minor cannabinoid, it also serves as a critical tool for studying structure-activity relationships within the endocannabinoid system.
Details
Cannabigerolic Acid (CAS 25555-57-1) is the fundamental biogenic precursor and "mother cannabinoid" in the cannabis plant, serving as the central biosynthetic intermediate from which other major cannabinoids—such as THCA, CBDA, and CBCA—are enzymatically derived. This carboxylic acid-containing compound exhibits inherent bioactive properties, including potential anti-inflammatory and neuroprotective effects, and is increasingly studied for its role in early-stage cannabis biosynthesis and its direct therapeutic applications in medicinal research.
Details
Cannabivarol (CAS 33745-21-0) is a cannabinoid derivative with potential analgesic and neuroprotective properties. Its structural complexity and lipophilicity present challenges in drug development but also offer opportunities for targeted therapeutic applications.
Details
Contact Us
1st Floor, No. 477, Huancheng West Road, Nanqiao Town, Fengxian District, Shanghai,China
sales@qxscientific.com
+86 -13701740203
IPv6 Network Supported |
Sitemap |
XML |
Blog |
Privacy Policy
Leave A Message
Scan to Wechat/Whatsapp :
English
English
Español
Português
